Cabbacis Stock Price, News & Analysis

Cabbacis Inc (OTCQB: CABI) is a U.S. federally licensed tobacco-product manufacturer focused on developing and commercializing patented, reduced-nicotine tobacco products under its iBlend™ brand. The company describes its mission as advancing tobacco harm-reduction alternatives for the world’s large population of smokers by creating cigarettes and vaporizer pods that are predominately tobacco and include hemp.

The iBlend™ product line in development centers on reduced-nicotine cigarettes and vaporizer pods that combine tobacco with non-intoxicating hemp. According to the company, these products are intended to assist smokers or vapers in smoking or vaping less, reducing nicotine exposure and dependence, transitioning to less harmful tobacco products, and increasing quit attempts. Cabbacis also states that it plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp, as well as vaporizer pods that use conventional-nicotine tobacco with hemp.

Business focus and product concept

Cabbacis emphasizes reduced-nicotine cigarettes that contain about 95 percent less nicotine than conventional cigarette brands, referencing independent research on reduced-nicotine cigarettes without hemp. The company reports that its patented iBlend™ cigarettes in development combine reduced-nicotine tobacco with hemp flower, which it believes improves product acceptability and may potentially improve effectiveness due to non-THC cannabinoids. Both the cigarette and vaporizer pod concepts are framed as harm-reduction tobacco products rather than nicotine-free products.

The company highlights that both types of iBlend™ products in development are predominately tobacco and include hemp. It also notes that it stands ready or plans to move forward with reduced-nicotine tobacco cigarettes and little cigars without hemp, alongside vaporizer pods that can incorporate conventional-nicotine or reduced-nicotine tobacco with hemp.

Clinical trial results reported by the company

Cabbacis has reported results from a pilot clinical trial conducted by the Rose Research Center on smokers using four types of reduced-nicotine tobacco cigarettes made by the company. In this study, three iBlend™ cigarette types contained reduced-nicotine tobacco with different hemp levels (5%, 10%, and 20%), and a fourth type contained reduced-nicotine tobacco without hemp. The nicotine content of all four types was reduced by approximately 95 percent compared with mainstream American cigarette brands.

According to the company’s description of the trial, all four Cabbacis cigarette types were highly rated for satisfaction on the standardized mCEQ questionnaire and significantly reduced cravings for participants’ usual brand cigarettes during three-hour ad libitum use sessions following overnight abstinence. The company also reports that the three hemp-containing iBlend™ cigarettes produced lower exhaled carbon monoxide (CO) levels than the non-hemp reduced-nicotine cigarette, with the 20 percent hemp iBlend™ cigarette showing a statistically significant reduction at the 95 percent confidence level.

Patent portfolio and intellectual property

Cabbacis places strong emphasis on its intellectual property. The company reports a worldwide patent portfolio of 34–35 issued patents and various pending patent applications held by its subsidiary Cabbacis LLC, including multiple U.S. patents. These patents primarily cover tobacco-hemp combinations in cigarettes and vaporizer pods, as well as vaporizer pods for oral electronic vaporizers that blend reconstituted tobacco and hemp.

The company states that it holds patents across key markets such as the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico, Brazil and other countries where it notes that approximately two-thirds of the world’s smokers reside. Cabbacis reports that it holds several U.S. patents on vaporizer pods containing tobacco and hemp, including a patent that covers vaporizer pods comprising blends of conventional-nicotine reconstituted tobacco and hemp, and separately, reduced-nicotine reconstituted tobacco and hemp.

Regulatory pathway and development stage

Cabbacis describes itself as a development-stage company with no revenue in recent reporting periods. It has referenced work toward Premarket Tobacco Product Applications (PMTAs) with the U.S. Food and Drug Administration (FDA) for its reduced-nicotine iBlend™ products. The company links its strategy to an FDA proposed rule that, if finalized, would limit nicotine levels in cigarettes to make them minimally or nonaddictive.

In its communications, Cabbacis notes that it intends to pursue FDA authorization for its products and, in parallel with the U.S. regulatory process, to market its technology and products internationally through licensing and partnership opportunities. The company also indicates that it has launched or qualified Regulation A (Tier 2) offerings to raise capital for product development, commercialization expenses, FDA-related costs for PMTAs, tobacco and hemp plantings, general corporate purposes and potential acquisitions.

Capital markets and trading venue

Cabbacis states that its common stock trades on the OTCQB market under the symbol CABI. The company has reported that its shares have obtained DTC eligibility, allowing electronic clearing and settlement of its common stock through the Depository Trust Company. Cabbacis has also highlighted efforts to expand its visibility among institutional and other investors, including engaging an investor relations firm and participating in virtual investor conferences.

Corporate structure and operations

The company describes Cabbacis LLC as a wholly owned subsidiary of Cabbacis Inc that holds its worldwide patent portfolio. Cabbacis characterizes itself as a U.S. federally licensed tobacco-product manufacturer and, in some communications, as a plant biotech company focused on tobacco harm-reduction products. It has referenced an established production facility and required licenses in the context of its ability to support future commercialization, while emphasizing that its current focus is on development, testing and regulatory preparation.

Positioning within tobacco harm reduction

Across its public statements, Cabbacis consistently frames its iBlend™ cigarettes and vaporizer pods as tobacco harm-reduction products aimed at the world’s large population of smokers. The company references independent research on reduced-nicotine cigarettes without hemp, which has shown reductions in cigarettes smoked per day, nicotine dependence and exposure, as well as increases in quit attempts and smoke-free days. Cabbacis states that it believes including hemp flower in reduced-nicotine cigarettes may improve sensory characteristics and product acceptability, and may potentially improve effectiveness due to non-THC cannabinoids.

According to the company, its patented iBlend™ products are intended to offer smokers and vapers additional choices that can help them smoke or vape less, transition to less harmful tobacco products, and increase quit attempts, while remaining within the category of tobacco and nicotine products rather than eliminating nicotine entirely.

FAQs about Cabbacis Inc (CABI)